3 results
PHASE IIPrimary ObjectiveThe primary objective of the Phase II portion of the study is to estimate the efficacy as measured by radiographic progression-free survival of IPATASERTIB (GDC-0068) (dosed at either 400 mg or 200 mg daily) + abirateroneā¦
The primary objective is to investigate if thermal ablation of breast tumors less than 2cm with < 25% DCIS is effective in terms of the number of tumors in which complete ablation is found on pathology result.
This study will evaluate the safety, tolerability, and pharmacokinetics of idasanutlin as a single agent and the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin in combination with either chemotherapy or venetoclax inā¦